Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 5, Pages 774-776Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.21
Keywords
-
Categories
Funding
- NCATS NIH HHS [UL1 TR000064] Funding Source: Medline
- NHLBI NIH HHS [U01 HL105198, U01HL105198, U19 HL065962, R01 HL105993] Funding Source: Medline
- NIGMS NIH HHS [R24 GM061374, U01 GM074492, R24 GM61374, U01 GM061374] Funding Source: Medline
- NINDS NIH HHS [R01 NS073346] Funding Source: Medline
Ask authors/readers for more resources
The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available